Roche Ends Development of Several Drugs

Among them, lampalizumab had fared poorly in phase 3 tests

In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates.

The casualties:

  • Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy due to age-related macular degeneration (AMD) and secondary to AMD. At one point, some analysts had predicted the drug could reach $2 billion in annual sales.
  • RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma that was in phase 1 testing.
  • RG6047, which was being tested in phase 1 for metastatic estrogen receptor-positive, HER2-negative breast cancer.
  • RG7203, a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

Source: FierceBiotech; February 1, 2018.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to or online at